Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 5, 2010, Pages 438-445

  Woodruff, Prescott G ^a,b   Wolff, Michael ^c   Hohlfeld, Jens M ^e   Krug, Norbert ^e   Dransfield, Mark T ^f   Sutherland, E Rand ^g   Criner, Gerard J ^h   Kim, Victor ^h   Prasse, Antje ⁱ   Nivens, Michael C ^d   Tetzlaff, Kay ^d,j   Heilker, Ralf ^c   Fahy, John V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g DEPARTMENT OF MEDICINE   (United States)

^h TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

Chronic bronchitis; Chronic obstructive pulmonary disease; Epidermal growth factor receptor; Mucins

Indexed keywords

BIBW 2948 BS; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MUCIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASEMENT MEMBRANE; BRONCHUS BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIUM CELL; EX VIVO STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GENE; GENE EXPRESSION; HEART INFARCTION; HUMAN; INTERNALIZATION; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY EPITHELIUM; SIDE EFFECT; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHOSCOPY; DOUBLE-BLIND METHOD; EPIDERMAL GROWTH FACTOR; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUCINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 77649157336     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200909-1415OC     Document Type: Article

References (20)

1. Hesselink AE, van der Windt DA, Penninx BW, Wijnhoven HA, Twisk JW, Bouter LM, van Eijk JT. What predicts change in pulmonary function and quality of life in asthma or COPD? J Asthma 2006;43:513-519.
2. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530-1535.
3. Reid LM, O'Sullivan DD, Bhaskar KR. Pathophysiology of bronchial hypersecretion. Eur J Respir Dis 1987;71:19-25.
4. Rogers DF. Airway goblet cells: responsive and adaptable front-line defenders. Eur Respir J 1994;7:1690-1706.
5. Saetta M, Turato G, Baraldo S, Zanin A, Braccioni F, Mapp CE, Maestrelli P, Cavallesco G, Papi A, Fabbri LM. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 2000;161:1016-1021.
6. Innes AL, Woodruff PG, Ferrando RE, Donnelly S, Dolganov GM, Lazarus SC, Fahy JV. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006;130:1102-1108.
7. Nadel JA, Burgel PR. The role of epidermal growth factor in mucus production. Curr Opin Pharmacol 2001;1:254-258.
8. Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 2005;128:3975-3984.
9. Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN, Rosenfeld MG. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 1987;328:820-823.
10. Felder S, LaVin J, Ullrich A, Schlessinger J. Kinetics of binding, endocytosis, and recycling of EGF receptor mutants. J Cell Biol 1992;117:203-212.
11. Glenney JR Jr, Chen WS, Lazar CS, Walton GM, Zokas LM, Rosenfeld MG, Gill GN. Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of antiphosphotyrosine antibodies. Cell 1988;52:675-684.
12. Sorkina T, Huang F, Beguinot L, Sorkin A. Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor. J Biol Chem 2002;277:27433-27441.
13. Woodruff P, Hohlfeld J, Krug N, Dransfeld M, Sutherland R, Criner G, Kim V, Prasse A, Nivens C, Tetzlaff K, et al. Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD [abstract]. Eur Resp J 2009;34:1803.
14. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007;104:15858-15863.
15. Falls JA, Baatz M, Arini N, Schape A, Binnig G, Linssen B. Object-oriented image analysis for high content screening: detailed quantification of cells and sub cellular structures with the cellenger software. Cytometry 2006;69:652-658.
16. Takeyama K, Dabbagh K, Jeong Shim J, Dao-Pick T, Ueki IF, Nadel JA. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 2000;164:1546-1552.
17. Takeyama K, Jung B, Shim JJ, Burgel PR, Dao-Pick T, Ueki IF, Protin U, Kroschel P, Nadel JA. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am J Physiol Lung Cell Mol Physiol 2001;280:L165-L172.
18. Takeyama K, Dabbagh K, Lee HM, Agusti C, Lausier JA, Ueki IF, Grattan KM, Nadel JA. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci USA 1999;96:3081-3086.
19. Nadel JA. Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respir Res 2001;2:85-89.
20. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (Iressa) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 2004;27:1081-1092.